Valuation: Astellas Pharma Inc.

Capitalization 4,37200Cr 2.78TCr 2.36TCr 2.16TCr 2.05TCr 3.8TCr 2,52300Cr 3.97TCr 25TCr 9.94TCr 1,21500Cr 10TCr 10TCr P/E ratio 2026 *
19.9x
P/E ratio 2027 * 15x
Enterprise value 4,79700Cr 3.06TCr 2.59TCr 2.37TCr 2.25TCr 4.17TCr 2,76800Cr 4.36TCr 28TCr 11TCr 1,33300Cr 11TCr 11TCr EV / Sales 2026 *
2.33x
EV / Sales 2027 * 2.13x
Free-Float
98.67%
Yield 2026 *
3.24%
Yield 2027 * 3.4%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.83%
1 week+13.85%
Current month+13.85%
1 month+14.82%
3 months+40.13%
6 months+53.18%
Current year+16.63%
More quotes
1 week 2,150.5
Extreme 2150.5
2,496
1 month 2,080.5
Extreme 2080.5
2,496
Current year 2,078
Extreme 2078
2,496
1 year 1,243.5
Extreme 1243.5
2,496
3 years 1,243.5
Extreme 1243.5
2,496
5 years 1,243.5
Extreme 1243.5
2,496
10 years 1,243.5
Extreme 1243.5
2,496
More quotes
Manager TitleAgeSince
Chief Executive Officer 63 10/02/2023
Director of Finance/CFO 54 01/11/2023
Compliance Officer - 01/04/2025
Director TitleAgeSince
Chairman 65 10/02/2023
Director/Board Member 63 01/06/2019
Director/Board Member 69 01/06/2021
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+0.83%+13.85%+70.34%+28.37% 2.78TCr
+3.66%+2.03%+21.58%+213.39% 95TCr
+0.93%+5.61%+56.34%+46.91% 58TCr
+2.01%+0.19%+15.78%+54.07% 39TCr
-0.64%+1.63%+23.88%+25.54% 37TCr
+1.82%+10.57%+38.48%+17.21% 30TCr
+0.89%+3.71%+19.67%+33.31% 30TCr
+0.57%+4.66%+22.77%+51.56% 30TCr
+4.49%+12.41%+29.06%+57.61% 21TCr
+5.29%-20.04%-53.46%-38.31% 21TCr
Average +1.64%+3.36%+24.44%+48.96% 36.25TCr
Weighted average by Cap. +1.59%+2.69%+24.58%+81.41%
See all sector performances

Financials

2026 *2027 *
Net sales 2,05900Cr 1.31TCr 1.11TCr 1.02TCr 963.81Cr 1.79TCr 1,18800Cr 1.87TCr 12TCr 4.68TCr 57TCr 4.92TCr 4.82TCr 2,15600Cr 1.37TCr 1.16TCr 1.07TCr 1.01TCr 1.87TCr 1,24400Cr 1.96TCr 12TCr 4.9TCr 60TCr 5.15TCr 5.04TCr
Net income 22TCr 140.31Cr 118.77Cr 108.85Cr 103.1Cr 191.43Cr 13TCr 200.15Cr 1.26TCr 500.79Cr 6.12TCr 526.19Cr 515.36Cr 29TCr 185.24Cr 156.8Cr 143.71Cr 136.11Cr 252.74Cr 17TCr 264.24Cr 1.67TCr 661.17Cr 8.08TCr 694.7Cr 680.39Cr
Net Debt 42TCr 270.54Cr 229.01Cr 209.9Cr 198.79Cr 369.13Cr 25TCr 385.93Cr 2.44TCr 965.65Cr 12TCr 1.01TCr 993.73Cr 21TCr 133.34Cr 112.87Cr 103.45Cr 98Cr 181.93Cr 12TCr 190.21Cr 1.2TCr 475.94Cr 5.82TCr 500.07Cr 489.78Cr
More financial data * Estimated data
Logo Astellas Pharma Inc.
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.
Employees
13,643
More about the company
Date Price Change Volume
06/26/06 2,441.00 ¥ +0.83% 1,05,17,100
05/26/05 2,421.00 ¥ +7.72% 1,79,10,200
04/26/04 2,247.50 ¥ +1.10% 66,60,400
03/26/03 2,223.00 ¥ +3.37% 98,47,800
02/26/02 2,150.50 ¥ +0.30% 93,02,900

Delayed Quote Japan Exchange, February 06, 2026 at 12:00 pm IST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,441.00JPY
Average target price
2,060.71JPY
Spread / Average Target
-15.58%
Consensus

Quarterly revenue - Rate of surprise